pulmonologyadvisor4d
Nasal Spray Formulation of Bumetanide Under FDA Review
The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
Quincy man becomes first Alzheimer’s patient to try nasal spray drug: ‘I’m hoping like heck’
Retired electrician Joe Walsh in December became the first Alzheimer’s patient to try a nasal spray used to treat other ...
Don’t use this nasal spray: FDA says it may cause ‘adverse’ effects
STATEN ISLAND, N.Y. — The U.S. Food and Drug Administration (FDA) has announced a recall of 89,312 bottles of a popular nasal ...
Over 89,000 Bottles of Nasal Spray Recalled By FDA—What to Know
There’s another recall to be aware of right now, and it involves nose spray. NeilMed Pharmaceuticals Inc., the manufacturer of NasoGel Spray, has issued an international recall of 89,312 of its sprays ...
Wicked Local3d
New treatment for Alzheimer's via nasal spray being piloted by Massachusetts man
The drug is designed to reduce inflammation in the brain and has been used on MS, cancer and migraine headaches.
FDA Greenlights U.S. Clinical Trial for New Nasal COVID-19 Vaccine
The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...
Massachusetts man first in country to try new Alzheimer's nasal spray treatment
Joe Walsh is now testing a new treatment using a nasal spray, the medication inside is called Foralumab. He is the first patient with Alzheimer's to try it. The Walsh family is hopeful. Foralumab is ...
WCVB Channel 5 Boston5d
Massachusetts man first in country to try new Alzheimer's nasal spray treatment
OKAY, HONEY, COME SIT HERE. TODAY, JOE IS TESTING SOMETHING NEW. A MEDICATION CALLED FOR INSIDE THIS NASAL SPRAY. ONE, TWO. THREE. JOE IS THE FIRST PATIENT WITH ALZHEIMER’S TO TRY THIS DRUG.
GlobalData on MSN5d
Keymed’s Stapokibart approved by NMPA for seasonal allergic rhinitis
China's National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application (NDA) for Stapokibart to treat seasonal allergic rhinitis. The approval is ...